ArticlesRandomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Introduction
The treatment of rheumatoid arthritis is traditionally characterised by escalation. The first step is non-steroidal anti-inflammatory drugs (NSAIDs), and then if necessary a sequence of progressively toxic second-line drugs (disease-modifying antirheumatic drugs) is introduced.1 There is evidence that some of these disease-modifying drugs provide a degree of disease control2 -ie, decrease disease activity but also maintain or improve physical function and retard radiographic joint damag3 However, both patients and physicians are dissatisfied with the long-term results of traditional therapy. A 1996 study suggested that early introduction of disease-modifying antirheumatic drugs may be more beneficial than delayed introduction for patients with recently diagnosed rheumatoid arthritis.4 Research is focused towards finding new, more effective drugs, reassessment and earlier use of existing drugs (such as corticosteroids5), and treatment with drug combinations.6
The COBRA trial (Combinatietherapie Bij Reumatoide Artritis) is an adaptation of the latter two optionsstep-down bridge therapy with corticosteroids in early rheumatoid arthritis.1 Our intention was to control disease rapidly at a very early stage, with agents that have overlapping windows of efficacy onset; and then, after 6 months to taper and stop the more toxic components while retaining disease control. We devised a regimen comprising a short period of high-dose oral prednisolone, rapidly tapered to a low maintenance dose. As the other components we chose methotrexate, commonly used as the disease-modifying drug of first choice in the USA, and sulphasalazine as the anchor drug to remain after the other two drugs were withdrawn. In Europe, sulphasalazine is commonly used as the disease-modifying drug of first choice.
We carried out a 56-week multicentre, randomised controlled trial among patients with early, active rheumatoid arthritis to study the degree of disease control afforded by a combination of sulphasalazine, methotrexate, and high/low oral prednisolone given in the first 28 weeks, compared with that achieved with sulphasalazine alone; and to find out whether control could be maintained on sulphasalazine alone, after sequential tapering and withdrawal of prednisolone and methotrexate in the second 28 weeks.
Section snippets
Patients
We recruited patients between May, 1993, and May, 1995, in ten centres (nine in the Netherlands, one in Belgium). To optimise the benefit/risk ratio in line with the study purpose, we applied strict eligibility criteria to include patients with early rheumatoid arthritis who had very active disease and were most likely to benefit from this intensive treatment, in whom effects could be easily measured, and in whom we believed adverse effects would be least likely. The inclusion criteria were: a
Results
The trial included 156 patients (figure 1). In one patient the protocol medication was stopped within 1 week because his disease was in spontaneous remission at baseline. Data for this patient are not reported. 76 patients received combination treatment, 79 sulphasalazine only. Five patients (3%, all in the sulphasalazine group) were lost to follow-up before week 56. In six patients (all withdrawn) the treatment assignment had to be revealed before week 56 for medical reasons.
The two treatment
Discussion
The combination of an extended oral pulse or corticosteroids, methotrexate, and sulphasalazine led to an immediate, substantial, and highly significant improvement of disease activity and physical function in most patients with severe, early rheumatoid arthritis. On a low daily maintenance dose of 7–5 mg prednisolone from week 7 onwards, this improvement continued ata slower pace up to week 28, and was almost double that of conventional treatment with sulphasalazine alone in all clinical
References (32)
- et al.
Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
Lancet
(1989) - et al.
Corticosteroid pulse therapy in active rheumatoid arthritis
Semin Arthritis Rheum
(1993) Management of rheumatoid arthritis
- et al.
Antirheumatic drugs: a proposed new classification
Arthritis Rheum
(1993) - et al.
The effectiveness of early treatment with ‘second-line’ antirheumatic drugs, a randomised, controlled trial
Ann Intern Med
(1996) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-dose Glucocorticoid Study Group
N Engl J Med
(1995)- et al.
Long acting drug combinations in rheumatoid arthritis: updated overview
- et al.
The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis
Arthritis Rheum
(1988) Adaptive biased urn randomisation in small strata when blinding is impossible
Biometrics
(1995)- et al.
Goldsmith CH. “Independent assessor” and “pooled index” as techniques for measuring treatment effects in rheumatoid arthritis
J Rheumatol
(1977)
Which traditional measures should be used in rheumatoid arthritis clinical trials:
Arthritis Rheum
The cooperating clinics committee of the American Rheumatism Association: a seven-day variability study of 499 patients with peripheral rheumatoid arthritis
Arthritis Rheum
Strength and function in the normal and rheumatoid hand
J Rheumatol
The MACTAR patient preference disability questionnaire: an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis
J Rheumatol
World Health Organisation and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials
J Rheumatol
Cats A Measurement of disability in Dutch rheumatoid arthritis patients
Clin Rheumatol
Cited by (1033)
Rationale, current state and opportunities in combining biologic disease modifying anti-rheumatic drugs in rheumatoid and psoriatic arthritis
2023, Revue du Rhumatisme (Edition Francaise)Glucocorticoids in rheumatoid arthritis: Balancing benefits and harm by leveraging the therapeutic window of opportunity
2023, Revue du Rhumatisme (Edition Francaise)